Zimvie

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Westminster, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ZimVie reports Q4 decline, focuses on innovation and challenges

ZimVie's Q4 2022 performance reflected challenges from disruptions in China and spine segment, leading to a decline in net sales.
Despite these challenges, the company showed strength in product innovation, operational efficiencies, and strategic partnerships.
Opportunities lie in focusing on growth through innovation, commercial success, and addressing challenges to improve performance.

ZimVie reports mixed Q1 performance, revises 2023 outlook upwards

ZimVie's Q1 2023 earnings call highlighted a mixed performance with a focus on innovation, financial discipline, and growth potential. While facing challenges in revenue generation and margins, the company's strategic approach and revised outlook indicate opportunities for market expansion and sustained growth.

ZimVie reports strong Q2 earnings, eyes growth in international markets

ZimVie's Q2 2023 earnings call highlighted robust financial performance, strategic initiatives in innovation, and growth prospects in dental and spine segments. The company aims to navigate competitive pressures, capitalize on market trends, and drive profitability through operational efficiencies and product differentiation.

ZimVie reports mixed Q3 results, focuses on innovation and efficiency

ZimVie's Q3 2023 performance reflected mixed results with growth in international dental sales but challenges in the U.S. and spine segments.
Operational efficiency improvements and cash position enhancement are strengths for the company.
Challenges include competition in spine, declining U.S. dental sales, and margin decline, while opportunities lie in market trends and strategic deals.

ZimVie sells spine business for $375 million, targets profitability

ZimVie's Q4 2023 performance reflects a strategic shift towards enhancing profitability through the sale of the spine business and cost optimization initiatives. While facing challenges in market conditions and debt reduction targets, the company aims to capitalize on opportunities for growth and improved financial health.

ZimVie focuses on dental business post-sale, eyes margin growth

ZimVie's Q1 2024 performance reflected a strategic shift towards the dental segment post-spine business sale.
While facing challenges in revenue generation and margin targets, the company's focus on efficiency and innovation bodes well for future growth.
Opportunities lie in margin improvement, market expansion, and new revenue streams through innovative dental solutions.

ZimVie reports robust Q2 revenue, eyes growth amidst short-term challenges

ZimVie's Q2 2024 performance showcased revenue growth and strong commercial traction in key portfolios
Despite short-term revenue challenges, the company reaffirmed full-year guidance and highlighted growth opportunities
Strategic partnerships and product advancements position ZimVie for continued market expansion and innovation
Maintaining financial discipline and focus on profitability amidst market dynamics are key priorities

ZimVie reports solid Q3 earnings, eyes North America for growth

ZimVie's Q3 performance showcased financial stability, strategic investments, and growth in key product portfolios. While challenges like debt management persist, the company's focus on efficiency and innovation positions them well for future opportunities in the dental market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Palm Beach Gardens, FL.

ZimVie Inc. (NASDAQ:ZIMV ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants David Saxon - Needham & Company Matt Miksic - Barclays Marissa Bych Thank you all for joining today's call. Earlier today, ZimVie released financial results for the quarter ended September 30, 2024.

ZimVie Inc. (ZIMV) Q3 2024 Earnings Call Transcript

PALM BEACH GARDENS, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Third Quarter Financial Results on October 30, 2024

ZimVie Inc. (NASDAQ:ZIMV ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 AM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants David Saxon - Needham & Company Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

ZimVie Inc. (ZIMV) Q2 2024 Earnings Call Transcript

Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings Addition of Premium Restorative Components Enhances ZimVie's End-to-End Implant Offerings

ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components

PALM BEACH GARDENS, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Second Quarter Financial Results on August 1, 2024

PALM BEACH GARDENS, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced that the company will be participating in two upcoming investor conferences.

ZimVie to Participate in Upcoming Investor Conferences

ZimVie Inc. (NASDAQ:ZIMV ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Vafa Jamali - President and CEO Richard Heppenstall - CFO Conference Call Participants Matt Miksic - Barclays Operator Good afternoon and welcome to ZimVie's First Quarter 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.

ZimVie Inc. (ZIMV) Q1 2024 Earnings Call Transcript

PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report First Quarter Financial Results on May 8, 2024

MIAMI--(BUSINESS WIRE)-- #Acquisition--H.I.G. Capital completed the acquisition of the Spine division of ZimVie, Inc., renamed Highridge Medical.

H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical

Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business

ZimVie Announces Closing of Sale of Spine Business

WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.

ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript

WESTMINSTER, Colo., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full-year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Newest implant innovation is designed for immediacy and peri-implant health Newest implant innovation is designed for immediacy and peri-implant health

ZimVie Announces Launch of Next-Generation TSX® Implant in Japan

ZimVie's stock has doubled since reporting Q3 earnings, causing investors to wonder about the company's future. The company's Q3 revenues declined less than expected and the company raised full-year guidance. More importantly, ZimVie's decision to sell its spine business for $375 million jettisons an underperforming segment while solving a debt overhang.

ZimVie: Focusing On Higher Growth Dental Business (Rating Upgrade)

ZimVie Inc. (NASDAQ:ZIMV ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call.

ZimVie Inc. (ZIMV) Q3 2023 Earnings Call Transcript

WESTMINSTER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the first patient in the United States has received the newly approved 4.5mm Mobi-C® Cervical Disc. Introduced in France in 2004, Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. The smaller 4.5mm height Mobi-C implants, available in seven footprints to match patient anatomy, were approved by the FDA in August of this year.

ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-C® Cervical Disc

Cano Health

Carter's

Sunstone Hotel Investors

Virgin Galactic

Service Properties Trust

Territorial Bancorp

While it's an uncomfortable topic, every investor must face the prospect of stocks to sell. Like it or not, market success doesn't just come down to picking winners.

Brace for Impact: 7 Stocks to Sell Amid Rising Troubles

New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio

ZimVie Announces the Launch of Azure™ Multi-Platform Product Solutions

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.

ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch

WESTMINSTER, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 1, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023

New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market

ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane

Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie and Brainlab will cooperate on achieving compatibility between ZimVie's Vital™ and Virage ® fixation systems with the Brainlab spine and trauma technologies for global co-marketing purposes

ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, ZimVie Inc. (ZIMV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

News for Zimvie Stock (ZIMV)